CERS Gets BARDA Funding, EPZM Abuzz, ZSAN Awaits Data In Q1 2017

Zosano Pharma Corp. (ZSAN) has enrolled the first subject in a pivotal efficacy trial of its ZP-Triptan patch treatment for acute migraine. The company expects to report pivotal efficacy data from the trial in the first quarter of 2017.

from RTT - Biotech http://ift.tt/1WY2s9G
via IFTTT